Rhythm names chief scientific officer

Wednesday, November 30, 2011

Rhythm has named Lex Van der Ploeg, PhD, chief scientific officer. Van der Ploeg brings to Rhythm more than 25 years of drug development experience in obesity, metabolic diseases, and other therapeutic areas.

[Read More]

Agios raises $78 million in financing

Thursday, November 17, 2011

Agios Pharmaceuticals has secured $78 million in an oversubscribed Series C financing. The proceeds of this financing will be used to advance the company’s rapidly emerging portfolio of cancer metabolism therapeutics into the clinic and to expand research and development into inborn errors of metabolism (IEMs), a group of genetic disorders with high unmet medical need.

[Read More]

Acceleron, Celegene collaborate

Wednesday, August 3, 2011

Acceleron Pharma and Celgene have entered into a joint development and commercialization agreement for ACE-536 for the treatment of anemia. The companies already have a collaboration around sotatercept (ACE-011) entered in 2008. Under the new agreement, the companies will collaborate to develop both products and potentially others for treating anemia across a wide range of indications.

[Read More]